

04-30-01

A/Box Seg.

10/27/01  
19631  
P-10C Please type a plus sign (+) inside this box → PTO/SB/05 (03-01)  
Approved for use through 10/31/2002. OMB 0651-0032  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY  
PATENT APPLICATION  
TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. P01925US2

First Inventor Martin M. Matzuk et al.

Title OVARY-SPECIFIC GENES AND, etc.

Express Mail Label No. EK102725416US

P  
11091844864S  
11091844864U  
11091844864L  
11091844864D  
11091844864

04/27/01

## APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1.  Fee Transmittal Form (e.g., PTO/SB/17)  
(Submit an original, and a duplicate for fee processing)

2.  Applicant claims small entity status.

3.  Specification [Total Pages 63]

(preferred arrangement set forth below)

- Descriptive title of the invention
- Cross Reference to Related Applications
- Statement Regarding Fed sponsored R & D
- Reference to sequence listing, a table, or a computer program listing appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings (if filed)
- Detailed Description
- Claim(s)
- Abstract of the Disclosure

4.  Drawing(s) (35 U.S.C. 113) [Total Sheets 29]

5. Oath or Declaration [Total Pages ]

a.  Newly executed (original or copy)

b.  Copy from a prior application (37 CFR 1.63(d))  
(for continuation/divisional with Box 18 completed)

i.  **DELETION OF INVENTOR(S)**  
Signed statement attached deleting  
inventor(s) named in the prior application,  
see 37 CFR 1.63(d)(2) and 1.33(b).

6.  Application Data Sheet. See 37 CFR 1.76

ADDRESS TO: Box Patent Application  
Commissioner for Patents  
Washington, DC 20231

7.  CD-ROM or CD-R in duplicate, large table or  
Computer Program (Appendix)

8.  Nucleotide and/or Amino Acid Sequence Submission  
(if applicable, all necessary)

a.  Computer Readable Form (CRF)

b. Specification Sequence Listing on:

i.  CD-ROM or CD-R (2 copies); or ii.  paper

c.  Statements verifying identity of above copies

## ACCOMPANYING APPLICATIONS PARTS

9.  Assignment Papers (cover sheet & document(s))

10.  37 CFR 3.73(b) Statement  
(when there is an assignee)  Power of Attorney

11.  English Translation Document (if applicable)

12.  Information Disclosure Statement (IDS)/PTO-1449  Copies of IDS Citations

13.  Preliminary Amendment

14.  Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)  
Certified Copy of Priority Document(s)

15.  (if foreign priority is claimed)

16.  Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i).

17.  Other: \_\_\_\_\_

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

 Continuation  Divisional  Continuation-in-part (CIP) of prior application No.: US99/25209

Prior application information: Examiner N/A Group / Art Unit: N/A

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

## 19. CORRESPONDENCE ADDRESS

Customer Number or Bar Code Label \_\_\_\_\_ or  Correspondence address below

Name	FULBRIGHT & JAWORSKI L.L.P. Melissa D. Schwaller, Ph.D.		
Address	1301 McKinney, Suite 5100		
City	Houston	State	TX
Country	US	Telephone	(713) 651-7732
		Zip Code	77010-3095
		Fax	(713) 651-5246

Name (Print/Type)	Melissa D. Schwaller	Registration No. (Attorney/Agent)	46,089
Signature	Melissa D. Schwaller		Date April 27, 2001

04/27/01  
JC951 U.S. PTO

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision.

**TOTAL AMOUNT OF PAYMENT** (\$ 1110.00)

## Complete if Known

Application Number	Not Yet Assigned
Filing Date	April 27, 2001
First Named Inventor	Martin M. Matzuk et al.
Examiner Name	Not Yet Assigned
Group Art Unit	N/A
Attorney Docket No.	P01925US2

## METHOD OF PAYMENT

1.  The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit Account Number

06-2375

Deposit Account Name

Fulbright & Jaworski L.L.P.

Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17

Applicant claims small entity status. See 37 CFR 1.27

2.  Payment Enclosed

Check  Credit Card  Money Order  Other

## FEE CALCULATION (continued)

### 3. ADDITIONAL FEES

Large Entity Fee Code	Fee (\$)	Small Entity Fee Code	Fee (\$)	Fee Description	Fee Paid
105	130	205	65	Surcharge - late filing fee or oath	
127	50	227	25	Surcharge - late provisional filing fee or cover sheet	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for ex parte reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	390	216	195	Extension for reply within second month	
117	890	217	445	Extension for reply within third month	
118	1,390	218	695	Extension for reply within fourth month	
128	1,890	228	945	Extension for reply within fifth month	
119	310	219	155	Notice of Appeal	
120	310	220	155	Filing a brief in support of an appeal	
121	270	221	135	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive - unavoidable	
141	1,240	241	620	Petition to revive - unintentional	
142	1,240	242	620	Utility issue fee (or reissue)	
143	440	243	220	Design issue fee	
144	600	244	300	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Processing fee under 37 CFR 1.17(q)	
126	180	126	180	Submission of Information Disclosure Stmt	
581	40	581	40	Recording each patent assignment per property (times number of properties)	
146	710	246	355	Filing a submission after final rejection (37 CFR 1.129(a))	
149	710	249	355	For each additional invention to be examined (37 CFR 1.129(b))	
179	710	279	355	Request for Continued Examination (RCE)	
169	900	169	900	Request for expedited examination of a design application	

Other fee (specify) \_\_\_\_\_

\*Reduced by Basic Filing Fee Paid

**SUBTOTAL (3) (\$)**

Complete if applicable

SUBMITTED BY	Name (print/type)	Melissa D. Schwaller	Registration No. (Attorney/Agent)	46,089	Telephone	(713) 651-7732
Signature		Melissa D. Schwaller			Date	April 27, 2001

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EK102725416US, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: April 27, 2001 Signature: *Melissa D. Schwaller* (Melissa Schwaller)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.:	To be assigned	§	Docket No.:	P01925US2
Filing Date:	April 27, 2001	§		
Applicants:	Matzuk et al.	§		
Title:	Ovary-Specific Genes and Proteins	§		

Box Patent Application  
Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Applicants respectfully request the entry of the present statement in regard to the enclosed sequence listing in the above-referenced application. The submitted materials include a computer readable form and paper copy of a sequence listing for the sequences found in the application (SEQ ID NO: 1-25). Applicants state that the information recorded in the computer readable form of the sequence listing is identical to the written sequence listing. Applicants also state that the submission, filed in accordance with 37 CFR 1.821(g), does not include new matter. The sequences found in the sequence listing are identical to those found in the application.

If you have any questions regarding the above-referenced application, please do not hesitate to contact me.

Respectfully submitted,

*Melissa D. Schwaller*

Melissa D. Schwaller, Ph.D.  
Registration No. 46,089

Date: 04-27-01

Fulbright & Jaworski L.L.P.  
1301 McKinney, Suite 5100  
Houston, Texas 77010-3095  
(713) 651-7732